{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:07:05Z","timestamp":1787501225632,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012131","name":"Department of Science and Technology of Liaoning Province","doi-asserted-by":"publisher","award":["2023-MSLH-363"],"award-info":[{"award-number":["2023-MSLH-363"]}],"id":[{"id":"10.13039\/501100012131","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department of Science and Technology of Liaoning Province,China","award":["2022JH2\/101500012"],"award-info":[{"award-number":["2022JH2\/101500012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-025-00545-4","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T07:34:04Z","timestamp":1753083244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Post-marketing safety signals of anifrolumab in systemic lupus erythematosus: a pharmacovigilance study based on FAERS"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3209-7184","authenticated-orcid":false,"given":"Yuzhe","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2978-1413","authenticated-orcid":false,"given":"Jingyi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7371-917X","authenticated-orcid":false,"given":"Jun","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"545_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1146\/annurev-immunol-101921-042422","volume":"41","author":"S Caielli","year":"2023","unstructured":"Caielli S, Wan Z, Pascual V. Systemic lupus erythematosus pathogenesis: interferon and beyond. Annu Rev Immunol. 2023;41:533\u201360. https:\/\/doi.org\/10.1146\/annurev-immunol-101921-042422.","journal-title":"Annu Rev Immunol"},{"key":"545_CR2","doi-asserted-by":"publisher","first-page":"e000261","DOI":"10.1136\/lupus-2018-000261","volume":"5","author":"JM Riggs","year":"2018","unstructured":"Riggs JM, Hanna RN, Rajan B, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5:e000261. https:\/\/doi.org\/10.1136\/lupus-2018-000261.","journal-title":"Lupus Sci Med"},{"key":"545_CR3","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s40265-021-01604-z","volume":"81","author":"ED Deeks","year":"2021","unstructured":"Deeks ED. Anifrolumab: first approval. Drugs. 2021;81:1795\u2013802. https:\/\/doi.org\/10.1007\/s40265-021-01604-z.","journal-title":"Drugs"},{"key":"545_CR4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1080\/19420862.2015.1007810","volume":"7","author":"L Peng","year":"2015","unstructured":"Peng L, Oganesyan V, Wu H, et al. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-\u03b1 receptor 1 antibody. mAbs. 2015;7:428\u201339. https:\/\/doi.org\/10.1080\/19420862.2015.1007810.","journal-title":"mAbs"},{"key":"545_CR5","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1136\/ard-2023-225445","volume":"83","author":"T Baker","year":"2024","unstructured":"Baker T, Sharifian H, Newcombe PJ, et al. Type I interferon Blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials. Ann Rheum Dis. 2024;83:1018\u201327. https:\/\/doi.org\/10.1136\/ard-2023-225445.","journal-title":"Ann Rheum Dis"},{"key":"545_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3389\/fimmu.2018.00427","volume":"9","author":"S Malkiel","year":"2018","unstructured":"Malkiel S, Barlev AN, Atisha-Fregoso Y, et al. Plasma cell differentiation pathways in systemic lupus erythematosus. Front Immunol. 2018;9:427. https:\/\/doi.org\/10.3389\/fimmu.2018.00427.","journal-title":"Front Immunol"},{"key":"545_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41584-023-00948-y","volume":"19","author":"S Fasano","year":"2023","unstructured":"Fasano S, Milone A, Nicoletti GF, et al. Precision medicine in systemic lupus erythematosus. Nat Rev Rheumatol. 2023;19:331\u201342. https:\/\/doi.org\/10.1038\/s41584-023-00948-y.","journal-title":"Nat Rev Rheumatol"},{"key":"545_CR8","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1186\/ar4492","volume":"16","author":"A Goldberg","year":"2014","unstructured":"Goldberg A, Geppert T, Schiopu E, et al. Dose-escalation of human anti-interferon-\u03b1 receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther. 2014;16:R57. https:\/\/doi.org\/10.1186\/ar4492.","journal-title":"Arthritis Res Ther"},{"key":"545_CR9","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.39962","volume":"69","author":"R Furie","year":"2017","unstructured":"Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti\u2013interferon-\u03b1 receptor monoclonal antibody, in moderate\u2010to\u2010severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69:376\u201386. https:\/\/doi.org\/10.1002\/art.39962.","journal-title":"Arthritis Rheumatol"},{"key":"545_CR10","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1:e208\u201319. https:\/\/doi.org\/10.1016\/S2665-9913(19)30076-1.","journal-title":"Lancet Rheumatol"},{"key":"545_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1912196.","journal-title":"N Engl J Med"},{"key":"545_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/14397595.2019.1583833","volume":"30","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y, Takeuchi T, Okada M, et al. Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: a multicenter, phase 2, open-label study. Mod Rheumatol. 2020;30:101\u20138. https:\/\/doi.org\/10.1080\/14397595.2019.1583833.","journal-title":"Mod Rheumatol"},{"key":"545_CR13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","volume":"81","author":"D Jayne","year":"2022","unstructured":"Jayne D, Rovin B, Mysler EF, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022;81:496\u2013506. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221478.","journal-title":"Ann Rheum Dis"},{"key":"545_CR14","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/art.41598","volume":"73","author":"WW Chatham","year":"2021","unstructured":"Chatham WW, Furie R, Saxena A, et al. Long-Term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase II Open\u2010Label extension study. Arthritis Rheumatol (Hob N j). 2021;73:816\u201325. https:\/\/doi.org\/10.1002\/art.41598.","journal-title":"Arthritis Rheumatol (Hob N j)"},{"key":"545_CR15","doi-asserted-by":"publisher","first-page":"e000252","DOI":"10.1136\/lupus-2017-000252","volume":"5","author":"R Tummala","year":"2018","unstructured":"Tummala R, Rouse T, Berglind A, et al. Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers. Lupus Sci Med. 2018;5:e000252. https:\/\/doi.org\/10.1136\/lupus-2017-000252.","journal-title":"Lupus Sci Med"},{"key":"545_CR16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10:796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048.","journal-title":"Int J Med Sci"},{"key":"545_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519\u201323. https:\/\/doi.org\/10.1002\/pds.1001.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"545_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483\u20136. https:\/\/doi.org\/10.1002\/pds.677.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"545_CR19","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1210\/jc.2009-2546","volume":"95","author":"SA Rivkees","year":"2010","unstructured":"Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab. 2010;95:3260\u20137. https:\/\/doi.org\/10.1210\/jc.2009-2546.","journal-title":"J Clin Endocrinol Metab"},{"key":"545_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, et al. A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54:315\u201321. https:\/\/doi.org\/10.1007\/s002280050466.","journal-title":"Eur J Clin Pharmacol"},{"key":"545_CR21","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","volume":"403","author":"A Hoi","year":"2024","unstructured":"Hoi A, Igel T, Mok CC, et al. Systemic lupus erythematosus. Lancet (Lond Engl). 2024;403:2326\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(24)00398-2.","journal-title":"Lancet (Lond Engl)"},{"key":"545_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 update of the joint European league against rheumatism and European renal association-european dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79:713\u201323. https:\/\/doi.org\/10.1136\/annrheumdis-2020-216924.","journal-title":"Ann Rheum Dis"},{"key":"545_CR23","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/BOR.0000000000000527","volume":"30","author":"A Ugarte","year":"2018","unstructured":"Ugarte A, Danza A, Ruiz-Irastorza G. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. Curr Opin Rheumatol. 2018;30:482\u20139. https:\/\/doi.org\/10.1097\/BOR.0000000000000527.","journal-title":"Curr Opin Rheumatol"},{"key":"545_CR24","doi-asserted-by":"publisher","first-page":"103612","DOI":"10.1016\/j.autrev.2024.103612","volume":"23","author":"M Gatto","year":"2024","unstructured":"Gatto M, Zen M, Cruciani C, et al. Navigating the landscape of SLE treatment: an expert viewpoint on the rationality and limitations of early biologic intervention. Autoimmun Rev. 2024;23:103612. https:\/\/doi.org\/10.1016\/j.autrev.2024.103612.","journal-title":"Autoimmun Rev"},{"key":"545_CR25","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/annrheumdis-2021-221847","volume":"81","author":"IN Bruce","year":"2022","unstructured":"Bruce IN, Furie RA, Morand EF, et al. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2\/3 trials. Ann Rheum Dis. 2022;81:962\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221847.","journal-title":"Ann Rheum Dis"},{"key":"545_CR26","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/mr\/road092","volume":"34","author":"Y Tanaka","year":"2024","unstructured":"Tanaka Y, Atsumi T, Okada M, et al. The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in japan: TULIP-LTE subgroup analysis. Mod Rheumatol. 2024;34:720\u201331. https:\/\/doi.org\/10.1093\/mr\/road092.","journal-title":"Mod Rheumatol"},{"key":"545_CR27","doi-asserted-by":"publisher","first-page":"e000910","DOI":"10.1136\/lupus-2023-000910","volume":"10","author":"D Jayne","year":"2023","unstructured":"Jayne D, Rovin B, Mysler E, et al. Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial. Lupus Sci Med. 2023;10:e000910. https:\/\/doi.org\/10.1136\/lupus-2023-000910.","journal-title":"Lupus Sci Med"},{"key":"545_CR28","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/1346-8138.17161","volume":"51","author":"L Xie","year":"2024","unstructured":"Xie L, Lopes Almeida Gomes L, Stone CJ, et al. An update on clinical trials for cutaneous lupus erythematosus. J Dermatol. 2024;51:885\u201394. https:\/\/doi.org\/10.1111\/1346-8138.17161.","journal-title":"J Dermatol"},{"key":"545_CR29","doi-asserted-by":"publisher","unstructured":"Claudio-Oliva A, Viedma-Mart\u00ednez M, Gallo-Pineda G, et al. Anifrolumab use in refractory dermatomyositis: a case report and literature review. Clin Exp Dermatol. 2024;llae476. https:\/\/doi.org\/10.1093\/ced\/llae476.","DOI":"10.1093\/ced\/llae476"},{"key":"545_CR30","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1001\/jamadermatol.2024.2160","volume":"160","author":"M Mansilla-Polo","year":"2024","unstructured":"Mansilla-Polo M, Mart\u00edn-Torregrosa D, Escutia-Mu\u00f1oz B, et al. Successful treatment of stimulator of interferon genes-associated vasculopathy of infantile onset SAVI syndrome with anifrolumab. JAMA Dermatol. 2024;160:899\u2013901. https:\/\/doi.org\/10.1001\/jamadermatol.2024.2160.","journal-title":"JAMA Dermatol"},{"key":"545_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/art.42392","volume":"75","author":"KC Kalunian","year":"2023","unstructured":"Kalunian KC, Furie R, Morand EF, et al. A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol (Hob NJ). 2023;75:253\u201365. https:\/\/doi.org\/10.1002\/art.42392.","journal-title":"Arthritis Rheumatol (Hob NJ)"},{"key":"545_CR32","doi-asserted-by":"publisher","first-page":"e005076","DOI":"10.1136\/rmdopen-2024-005076","volume":"11","author":"L Trefond","year":"2025","unstructured":"Trefond L, Chasset F, Jachiet M, et al. Efficacy of valaciclovir in preventing herpes Zoster in patients receiving anifrolumab. RMD Open. 2025;11:e005076. https:\/\/doi.org\/10.1136\/rmdopen-2024-005076.","journal-title":"RMD Open"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00545-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00545-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00545-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T07:34:05Z","timestamp":1753083245000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-025-00545-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["545"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00545-4","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Ethical approval was not required for this study because we used the FAERS database, which is a free open-access database.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}